TREATMENT METHODS
Disclosed are methods of treating rhinosinusitis of the upper airway passages in patients afflicted with said disease, which comprises administering at least once-a-day to the surfaces of said passages of said patients an amount of aerosolized particles of mometasone furoate as a monotherapy effective for treating said disease.
1 . A method of treating acute rhinosinusitis of the upper airway passages in patients afflicted with said disease, without the concomitant administration of an antibiotic, which comprises administering at least once-a-day to the surfaces of said passages of said patients an amount of aerosolized particles of mometasone furoate effective for treating said disease.
2 . The method of claim 1 , wherein said amount of mometasone furoate no ranges from about ranging from about 25 μg to about 1600 μg of aerosolized particles of mometasone furoate.
3 . The method of claim 2 , wherein said amount of mometasone furoate ranges from about 25 μg to about 800 μg.
4 . The method of claim 3 , wherein said amount of mometasone furoate ranges from about 25 μg to about 400 μg.
5 . The method of claim 4 , wherein said amount of mometasone furoate ranges from about 25 μg to about 200 μg.
6 . The method of claim 5 , wherein said amount of mometasone furoate ranges from about 25 μg to about 100 μg.
7 . The method of claim 1 , wherein said amount of mometasone furoate is about 100 μg, 200 μg or 400 μg.
8 . The method of claim 1 , wherein said amount of mometasone furoate is administered twice a day.
9 . The method of claim 1 , wherein the mometasone furoate is mometasone furoate monohydrate.
10 . The method of claim 1 , wherein the mometasone furoate is administered in the form of an aqueous suspension.
11 . The method of claim 1 , wherein the mometasone furoate is administered in the form of a dry powder.
12 . The method of claim 11 , wherein the mometasone furoate is anhydrous.
13 . A method of treating acute rhinosinusitis of the upper airway passages in patients afflicted with said disease without the concomitant administration of an antibiotic, which comprises administering at least once-a-day to the surfaces of said passages of said patients an amount of aerosolized particles of a corticosteroid effective for treating said disease.
14 . The method of claim 13 , wherein said corticosteroid is selected from the group consisting of dexamethasone, butoxicart, rofleponide, budesonide, deflazacort, ciclesonide, fluticasone, beclomethasone, loteprednol or triamcinolone.
15 . The method of claim 13 , wherein the corticosteroid is administered in the form of an aqueous suspension.
16 . The method of claim 13 , wherein the corticosteroid is administered in the form of a dry powder.
17 . The method of claim 13 , wherein the corticosteroid is fluticasone.
18 . The method of claim 17 , wherein the administered dose of fluticasone is 2 sprays of 50 μg of fluticasone propionate each in each nostril once daily.
19 . The method of claim 17 , wherein the administered dose of fluticasone is 1 spray of 50 μg of fluticasone propionate each in each nostril once daily.
20 . The method of claim 13 , wherein the corticosteroid is triamcinolone.
21 . The method of claim 20 , wherein the administered dose of triamcinolone is 220 μg per day as two sprays in each nostril once daily.
22 . The method of claim 20 , wherein the administered dose of triamcinolone is 110 μg per day as one spray in each nostril once daily.
23 . The method of claim 13 , wherein the corticosteroid is budesonide.
24 . The method of claim 23 , wherein the administered dose of budesonide is 64 μg per day administered as one spray per nostril of 32 μg once daily.